“We’ll be a meaningful player, even in the lung market"
US-based pharma group Bristol-Myers Squibb has come under pressure in the field of immuno-oncology, but the company’s CFO believes they are still in a strong position, also in the all-important lung cancer niche. He is open to looking at external innovation in one particular area.
BY MARTIN HAVTORN PETERSEN
“Bristol-Myers Squibb is in interesting times where we find ourselves in a very competitive second-line lung market. The first-line lung market continues to evolve with competitive dynamics there.”
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
